Characterization of anxiety-related responses in male rats following prolonged exposure to therapeutic doses of oral methylphenidate.
Increases in the rates of attention-deficit/hyperactivity disorder (ADHD) diagnosis and the prescribed use of methylphenidate (MPH) in recent years have raised concerns over the potential effects of early MPH exposure on brain structure and function in adulthood. Animal studies have shown that long-term MPH exposure can modify anxiety-related behaviors and related neural circuitry in adulthood. The present study employed a battery of behavioral tests and repeated testing to assess the long-term effects of MPH exposure on anxious responding. Male Wistar rats beginning on post-natal day 27 were exposed to 4 or 7 weeks of twice daily MPH administration at doses of 2, 3, or 5 mg/kg. MPH was administered orally and on weekdays only in order to approximate drug treatment in clinical populations. Behavioral testing began 18 days following the last drug administration. Our results indicate that prolonged oral MPH treatment at therapeutic doses has little or no enduring effects on anxious behaviors. However, a comparison of MPH groups that received treatment for 4 or 7 weeks suggests that the two treatment periods influenced anxious behaviors in observably different manners in adulthood; namely, a more prolonged period of exposure produced less anxiety relative to the shorter period of MPH exposure as indicated by behaviors in the light-dark transition, elevated plus-maze, and fear conditioning tests. These findings were interpreted as evidence of the importance of considering length of drug exposure in pre-clinical studies aimed at investigating the effects of MPH exposure in ADHD populations.
Britton
Gabrielle B
GB
Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Cognición, Cerebro y Conducta, Ciudad del Saber, Panamá. gbritton@indicasat.org.pa
Bethancourt
José A
JA
D000818:Animals; D001007:Anxiety / Q000209:etiology* / Q000523:psychology*; D001835:Body Weight / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000493:pharmacokinetics; D003216:Conditioning, Operant / Q000187:drug effects; D003624:Darkness; D004644:Emotions / Q000187:drug effects; D005106:Exploratory Behavior / Q000187:drug effects; D005239:Fear / Q000187:drug effects; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects* / Q000493:pharmacokinetics; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar
D000697:Central Nervous System Stimulants; D008774:Methylphenidate